Rchr
J-GLOBAL ID：201401024996540884   Update date: Aug. 02, 2022

Hayashi Hidetoshi

ハヤシ ヒデトシ | Hayashi Hidetoshi
Affiliation and department：
Kindai University

About Kindai University


Research field  (1)： Tumor diagnostics and therapeutics
Research keywords  (5)： Cancer of Unknown Primary ,  Lung Cancer ,  Gene analysis ,  medical oncology ,  immune checkpoint inhibitor
Research theme for competitive and other funds  (3)：
  • 2019 - 2022 Immune related gene-expression profiling for the combination of chemotherapy and PD-1/PD-L1 inhibition.
  • 2016 - 2018 Resistance mechanis of molecular targeted therapy and tumor micro environment as the immune-checkpoint inhibitor's biomarker
  • 2014 - 2017 未治療原発不明癌に対する次世代シークエンスを用いた原発巣推定に基づく治療 効果の意義を問う第 II 相試験
Papers (226)：
  • Satoru Hagiwara, Naoshi Nishida, Hiroshi Ida, Kazuomi Ueshima, Yasunori Minami, Masahiro Takita, Tomoko Aoki, Masahiro Morita, Hirokazu Cishina, Yoriaki Komeda, et al. Clinical implication of immune checkpoint inhibitor on the chronic hepatitis B virus infection. Hepatology Research. 2022
  • Yuichi Ozawa, Nobuyuki Yamamoto, Kouji Yamamoto, Kentaro Ito, Hirotsugu Kenmotsu, Hidetoshi Hayashi, Takehito Shukuya, Daichi Fujimoto, Shunichi Sugawara, Seiji Niho, et al. Creation of an Integrated Clinical Trial Database and Data Sharing for Conducting New Research by the Japan Lung Cancer Society. JTO clinical and research reports. 2022. 3. 5. 100317-100317
  • Hidetoshi Hayashi, Kimio Yonesaka, Atsushi Nakamura, Daichi Fujimoto, Koichi Azuma, Shinya Sakata, Motoko Tachihara, Satoshi Ikeda, Toshihide Yokoyama, Osamu Hataji, et al. Alternating therapy with osimertinib and afatinib for treatment-naive patients with EGFR-mutated advanced non-small cell lung cancer: A single-group, open-label phase 2 trial (WJOG10818L). Lung cancer (Amsterdam, Netherlands). 2022. 168. 38-45
  • Yoshinori Imamura, Kazunori Otsui, Kenta Mori, Koichi Kitagawa, Hideaki Okada, Akito Hata, Hidetoshi Hayashi, Taku Nose, Shinya Ohata, Yoshiharu Miyata, et al. Apixaban in Japanese patients with cancer-associated venous thromboembolism: a multi-center phase II trial. International journal of hematology. 2022. 115. 4. 499-507
  • Kohei Otsubo, Junji Kishimoto, Masahiko Ando, Hirotsugu Kenmotsu, Yuji Minegishi, Hidehito Horinouchi, Terufumi Kato, Eiki Ichihara, Masashi Kondo, Shinji Atagi, et al. Nintedanib plus chemotherapy for non-small cell lung cancer with IPF: a randomized phase 3 trial. The European respiratory journal. 2022
ｍore...
MISC (239)：
  • Kimio Yonesaka, Junko Tanizaki, Osamu Maenishi, Hisato Kawakami, Kaoru Tanaka, Hidetoshi Hayashi, Masayuki Takeda, Kazuko Sakai, Maki Kobayashi, Ryoto Yoshimoto, et al. EGFR inhibitor upregulates HER3 expression and enhances the efficacy of anti-HER3 antibody drug conjugate U3-1402. ANNALS OF ONCOLOGY. 2021. 32. S296-S296
  • 武田真幸, 武田真幸, 中川和彦, 林秀敏, 岩朝勤, 川上尚人, 渡邉諭美, 山本昇, 米盛勧, 小山隆文, et al. ベンダムスチン塩酸塩経口剤(SyB C-0501)の進行性固形がん患者に対する第1相臨床試験. 日本癌治療学会学術集会(Web). 2021. 59th
  • 金村宙昌, 田中薫, 鈴木慎一郎, 黒崎隆, 磯本晃佑, 岩朝勤, 白石直樹, 林秀敏, 武田真幸, 中川和彦. 気管支鏡検査時の迅速細胞診(ROSE)の成功に関連する因子の検討. 気管支学. 2021. 43
  • 加藤 了資, 林 秀敏. 【がんゲノム医療update】NGSを用いたマルチコンパニオン診断. 呼吸器内科. 2020. 38. 4. 301-305
  • 林 秀敏. 免疫療法時代における局所療法の意義 免疫チェックポイント阻害薬時代に期待される集学的治療、最新の話題と課題. 日本癌治療学会学術集会抄録集. 2020. 58回. SY9-4
ｍore...
Lectures and oral presentations  (4)：
  • Prognostic impact of EMT-related genes on post-operative prognosis in hepatocellular carcinoma.
    (AACR 103rd Annual Meeting 2011 2012)
  • 進行肺腺癌を対象としたゲフィチニブ/S-1併用療法第1層臨床試験
    (第51回日本肺癌学会総会 2010)
  • 進行肺腺癌を対象としたゲフェチニブ/S-1 併用療法第1相臨床試験
    (第92回日本肺癌学会関西支部会 2010)
  • ソラフェニブは肺癌細胞においてKRAS野生型に対しては
    (第8回日本臨床腫瘍学会総会 2010)
Education (2)：
  • 2009 - 2012 Kindai University
  • 1997 - 2003 Osaka University Medical School
Professional career (1)：
  • 医学博士 (近畿大学)
Work history (8)：
  • 2022/04 - 現在 Kindai University, Faculty of Medicine Department of Medical Oncology
  • 2020/04 - 2022/03 近畿大学医学部 内科学腫瘍内科 講師
  • 2015/10 - 2020/03 Kindai university hospital Department of Medical Oncology Lecturer
  • 2015/04 - 2015/09 Kindai university hospital Department of Medical Oncology Assistant professor
  • 2013/04 - 2015/03 Kishiwada City Hospital Department of Medical Oncology Director
Show all
Committee career (7)：
  • 2022/03 - 現在 Japanese Society of Medical Oncology Vice chair of the Specialist Examination Subcommittee
  • 2020/02 - 現在 International Association for the Study of Lung Cancer Membership committee
  • 2017 - 現在 日本臨床腫瘍学会 学術集会部会委員
  • 2017 - 現在 日本がん治療認定医機構 教育委員会専門部会委員
  • 2020/10 - 日本肺癌学会 データベース委員会委員
Show all
Awards (2)：
  • 2015/07 - 日本臨床腫瘍学会 日本臨床腫瘍学会奨励賞
  • 2008/06 - 西日本がん研究機構 西日本がん研究機構賞
Association Membership(s) (5)：
American Society of Clinical Oncology ,  日本臨床腫瘍学会 ,  THE JAPAN LUNG CANCER SOCIETY ,  THE JAPANESE SOCIETY OF INTERNAL MEDICINE ,  International Association for the Study of Lung Cancer
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in researchmap. For details, see here.

Return to Previous Page

TOP

BOTTOM